¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"genes, p53"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • protein p53
    ´Ü¹éÁúp53
  • caretaker genes
    °ü¸®À¯ÀüÀÚ
  • homologous genes
    »óµ¿À¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hox genes
    Ȥ½º À¯ÀüÀÚ, Hox À¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • p53 gene
    p53À¯ÀüÀÚ(¡­ë¶îîí­)
  • c2 genes
    C2 À¯ÀüÀÚ (¡­ë¶îîí­)
  • cancer suppressor genes
    ¾Ï¾ïÁ¦À¯ÀüÀÚ(äßåäð¤ë¶îîí­)
  • ced genes
    ced À¯ÀüÀÚ(¡­ë¶îîí­)
  • complementary genes
    »óº¸¼ºÀ¯ÀüÀÚ(ßÀÜÍàõë¶îîí­).
  • cooperating genes
    Çùµ¿À¯ÀüÀÚ
  • fcc genes
    FCC À¯ÀüÀÚ
  • hox genes
    Ȥ½º À¯ÀüÀÚ, Hox À¯ÀüÀÚ
  • multiple genes
    ´ÙÀ¯ÀüÀÚ.
  • multiple genes
    º¹¼öÀ¯ÀüÀÚ.
  • myogenic genes
  • reporter genes
    Á¤º¸Á¦°ø À¯ÀüÀÚ
  • retinoblastoma(RB) genes
    ¸Á¸·¾Æ¼¼Æ÷Á¾ À¯ÀüÀÚ
  • suicide genes
    ÀÚ»ì À¯ÀüÀÚ
  • tat genes
    tat À¯ÀüÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • C genes
    C À¯ÀüÀÚ(ë¶îîí­)
  • complementary genes
    »óº¸¼º À¯ÀüÀÚ(ßÓÜÍàõë¶îîí­)
  • housekeeping genes
    »ì¸² À¯ÀüÀÚ(ë¶îîí­)
  • J genes
    J À¯ÀüÀÚ(ë¶îîí­)
  • joining genes
    Á¢ÇÕÀ¯ÀüÀÚ(ïÈùêë¶îîí­)
  • luxury genes
    ƯȰÀ¯ÀüÀÚ(÷åüÀë¶îîí­)
  • reiterated genes
    ¹Ýº¹ À¯ÀüÀÚ(ÚãÜÖë¶îîí­)
  • syn genes
    ½Å À¯ÀüÀÚ(ë¶îîí­)
  • syntenic genes
    µ¿¿°»öü À¯ÀüÀÚ(ÔÒæøßäô÷ë¶îîí­)
  • two-genes-one-polypeptide chain
    ÀÌÀ¯ÀüÀÚ(ì£ë¶îîí­)- ÀÏ(ìé)Æú¸®ÆéŸÀÌµå »ç½½
  • ur genes
    ¿ø(ê«) À¯ÀüÀÚ
  • variable genes
    °¡º¯ºÎÀ§(ʦܨݻêÈ) À¯ÀüÀÚ (ë¶îîí­)
  • V genes
    V À¯ÀüÀÚ (ë¶îîí­)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
wt-p53 Wild-type p53
p53(+/+) p53
p53-/- p53 deficient
ISG IFN stimulated genes
mdr Multidrug resistance genes
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
genes, p53 Tumour suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
p53 <molecular biology, oncogene> A gene which encodes a protein that regulates cell growth and is able to cause potentially cancerous cells to destroy themselves.
In humans it is a 393 residue phosphoprotein that is a tumour suppressor gene rather than an oncogene, as it is frequently inactivated or mutated in tumours and transformed cells.
The gene is an antioncogene, and is often found mutated in smokers with lung cancer by a compound found in tobacco smoke, a polycyclic aromatic hydrocarbon called benzo[a]pyrene.
The protein it encodes is a phosphoprotein that is 53 kilodaltons in mass.
(24 Mar 1998)
p53-activating kinase <enzyme> Regulates p53 activity in saccharomyces cerevisiae; 810 amino acid residues; genbank u24167; do not confuse with pak I, protease-activated kinase
Registry number: EC 2.7.10.-
Synonym: pak1 gene product, yeast pak1
(26 Jun 1999)
protein p53 Nuclear phosphoprotein encoded by the p53 gene (genes, p53) whose normal function is to control cell proliferation. A mutant or absent p53 protein has been found in leukaemia, osteosarcoma, lung cancer, and colourectal cancer.
(12 Dec 1998)
breast cancer susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
cancer, breast, susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
genes Located in the nucleus of the cell, genes contain hereditary information that is transferred from cell to cell.
(09 Oct 1997)
genes, abl Retrovirus-associated DNA sequences (abl) originally isolated from the abelson murine leukaemia virus (ab-mulv). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukaemia.
(12 Dec 1998)
genes, apc Tumour suppressor genes located in the 5q21 region on the long arm of chromosome 5. The mutation of these genes is associated with familial adenomatous polyposis (apc stands for adenomatous polyposis coli) and gardner's syndrome, as well as some sporadic colourectal cancers.
(12 Dec 1998)
genes, arac Regulatory genes which encode a cyclic AMP receptor protein required for l-arabinose utilization in e. Coli. It is an example of positive control or regulation of gene expression in the bacterial operon.
(12 Dec 1998)
genes, archaeal The genetic material of archaea.
(12 Dec 1998)
genes, bacterial The genetic material of bacteria.
(12 Dec 1998)
genes, bcl-1 The B-cell leukaemia/lymphoma-1 genes, associated with various neoplasms when overexpressed. Overexpression results from the t(11;14) translocation, which is characteristic of mantle zone-derived B-cell lymphomas. The human c-bcl-1 gene is located at 11q13 on the long arm of chromosome 18.
(12 Dec 1998)
genes, bcl-2 The B-cell leukaemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.
(12 Dec 1998)
genes, BRCA1 Tumour suppressor genes located on human chromosome 17q12-21. The mutation of these genes is associated with the formation of familial breast and ovarian cancer.
(12 Dec 1998)
genes, breast cancer susceptibility Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. Howeverm, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. See related entries to: BRCA1; BRCA2; Breast cancer, familial.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Genes, p53 - »õâ Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
    Synonyms : Gene, TP53, Gene, p53, TP53 Gene, p53 Gene
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á